➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Merck
Express Scripts
Harvard Business School
AstraZeneca

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

ARIMIDEX Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Arimidex, and what generic alternatives are available?

Arimidex is a drug marketed by Ani Pharms Inc and is included in one NDA.

The generic ingredient in ARIMIDEX is anastrozole. There are twenty-four drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the anastrozole profile page.

US ANDA Litigation and Generic Entry Outlook for Arimidex

A generic version of ARIMIDEX was approved as anastrozole by ACCORD HLTHCARE on June 28th, 2010.

  Start Trial

Drug patent expirations by year for ARIMIDEX
Drug Prices for ARIMIDEX

See drug prices for ARIMIDEX

Recent Clinical Trials for ARIMIDEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jonsson Comprehensive Cancer CenterPhase 2
Medical College of WisconsinPhase 1
The Affiliated Hospital of Qingdao UniversityPhase 1

See all ARIMIDEX clinical trials

Pharmacology for ARIMIDEX
Drug ClassAromatase Inhibitor
Mechanism of ActionAromatase Inhibitors

US Patents and Regulatory Information for ARIMIDEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms Inc ARIMIDEX anastrozole TABLET;ORAL 020541-001 Dec 27, 1995 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ARIMIDEX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0296749 C970012 Netherlands   Start Trial PRODUCT NAME: ANASSTROZOLUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT; NAT. REGISTRATION NO/DATE: RVG 19123 19960905; FIRST REGISTRATION: GB 12619/0106 19950811
0296749 97C0023 France   Start Trial PRODUCT NAME: ANASTROZOLE, EVENTUELLEMENT SOUS LA FORME D UN SEL D ADDITION ACCEPTABLE EN MEDECINE PHARMACEUTIQUE; NAT REG. NO/DATE: NL 21126 19961227; FIRST REG.: 12619/0106 19950811
0296749 97C0032 Belgium   Start Trial PRODUCT NAME: ANASTROZOLUM; NAT. REGISTRATION NO/DATE: 624 IS 94 F 3 19961216; FIRST REGISTRATION: GB 12619/0106 19950811
0296749 SPC/GB96/004 United Kingdom   Start Trial PRODUCT NAME: ANASTROZOLE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT; REGISTRATION NO/DATE: UK 12619/0106 19950811
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Harvard Business School
Moodys
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.